Terms: = Uterine cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
21 results:
1. Targeted Therapies in the Treatment of uterine Serous Carcinoma.
Tymon-Rosario JR; Gorman M; Santin AD
Curr Treat Options Oncol; 2022 Dec; 23(12):1804-1817. PubMed ID: 36447064
[TBL] [Abstract] [Full Text] [Related]
2. Novel approaches for treatment of endometrial carcinoma.
Garg V; Jayaraj AS; Kumar L
Curr Probl Cancer; 2022 Oct; 46(5):100895. PubMed ID: 35986972
[TBL] [Abstract] [Full Text] [Related]
3. Value of metabolic parameters of primary lesions examined by 18F-FDG PET/CT for endometrial cancer in preoperative evaluation.
Gai QZ; Lv YB; Li GY; Zhang DQ; Gao Z; Fang XH
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2493-2502. PubMed ID: 33829435
[TBL] [Abstract] [Full Text] [Related]
4. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.
Charo LM; Plaxe SC
F1000Res; 2019; 8():. PubMed ID: 31231511
[TBL] [Abstract] [Full Text] [Related]
5. Surgical treatment of high stage endometrial cancer: current perspectives.
Vitale SG; Valenti G; Gulino FA; Cignini P; Biondi A
Updates Surg; 2016 Jun; 68(2):149-54. PubMed ID: 26826083
[TBL] [Abstract] [Full Text] [Related]
6. Expression of ER, PR, c-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract] [Full Text] [Related]
7. her-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
Kalogiannidis I; Petousis S; Bobos M; Margioula-Siarkou C; Topalidou M; Papanikolaou A; Vergote I; Agorastos T
Arch Gynecol Obstet; 2014 Dec; 290(6):1231-7. PubMed ID: 25022554
[TBL] [Abstract] [Full Text] [Related]
8. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract] [Full Text] [Related]
9. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
[TBL] [Abstract] [Full Text] [Related]
10. The prognostic significance of the triple negative phenotype in endometrial cancer.
Kothari R; Morrison C; Richardson D; Seward S; O'Malley D; Copeland L; Fowler J; Cohn DE
Gynecol Oncol; 2010 Aug; 118(2):172-5. PubMed ID: 20605625
[TBL] [Abstract] [Full Text] [Related]
11. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population.
Kitao K; Yoshida S; Kennedy S; Takemura N; Sugimoto M; Deguchi M; Ohara N; Maruo T
Reprod Sci; 2007 May; 14(4):349-57. PubMed ID: 17644807
[TBL] [Abstract] [Full Text] [Related]
13. The management of serous papillary uterine cancer.
Schwartz PE
Curr Opin Oncol; 2006 Sep; 18(5):494-9. PubMed ID: 16894299
[TBL] [Abstract] [Full Text] [Related]
14. her-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract] [Full Text] [Related]
15. Clinical significance of her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer.
Fanning J; Brown S; Phibbs G; Kramer T; Zaher A
Int J Gynecol Cancer; 2002; 12(3):286-9. PubMed ID: 12060450
[TBL] [Abstract] [Full Text] [Related]
18. The utilization of immunohistochemical prognostic factor in endometrial adenocarcinoma: is it cost effective?
Gürer IE; Simşek T; Erdoğan G; Atalay E; Zorlu CG; Karaveli S; Erman O
Eur J Gynaecol Oncol; 2000; 21(2):197-9. PubMed ID: 10843486
[TBL] [Abstract] [Full Text] [Related]
19. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract] [Full Text] [Related]
20. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma.
Bell JG; Minnick A; Reid GC; Judis J; Brownell M
Gynecol Oncol; 1997 Sep; 66(3):388-92. PubMed ID: 9299250
[TBL] [Abstract] [Full Text] [Related]
[Next]
